PIC
TLX

Portland Investment Counsel’s Telix Pharmaceuticals TLX Stock Holding History

Portland Investment Counsel’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.07M Hold
266,200
– – 0.86% 17
2026
Q1 		$2.55M Hold
266,200
– – 0.82% 16
2025
Q4 		$2.06M Buy
266,200
+138,200
+108% +$1.33M 0.62% 19
2025
Q3 		$1.22M Buy
+128,000
New +$1.57M 0.34% 27

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $15.3B AUM 25.33% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return

Portland Investment Counsel's TLX Position: Q2 2026 in Review

Portland Investment Counsel held its Telix Pharmaceuticals (TLX) position steady in Q2 2026 at 266,200 shares worth $3.07M. The position accounts for 0.86% of the portfolio, ranked #17.

Portland Investment Counsel first reported a position in TLX in Q3 2025 and has held it in 4 quarters since. 61 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • Portland Investment Counsel held 266,200 shares of Telix Pharmaceuticals worth $3.07M as of Q2 2026.
  • Portland Investment Counsel left its Telix Pharmaceuticals share count unchanged in Q2 2026.
  • Telix Pharmaceuticals made up 0.86% of Portland Investment Counsel's portfolio in Q2 2026, its #17 holding.
  • Portland Investment Counsel first reported a position in Telix Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 61 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on Portland Investment Counsel's 13F filing for Q2 2026, filed 13 Aug 2026.